Abstract
Mood disorders and suicidal behavior have moderate heritability and are associated with altered corticolimbic serotonin 1A receptor (5-HT1A) brain binding. However, it is unclear whether this reflects genetic effects or epigenetic effects of childhood adversity, compensatory mechanisms, or illness stress-related changes. We sought to separate such effects on 5-HT1A binding by examining high familial risk individuals (HR) who have passed through the age of greatest risk for psychopathology onset with and without developing mood disorder or suicidal behavior. PET imaging quantified 5-HT1A binding potential BPND using [11C]CUMI-101 in healthy volunteers (HV, N = 23) and three groups with one or more relatives manifesting early-onset mood disorder and suicide attempt: 1. unaffected HR (N = 23); 2. HR with lifetime mood disorder and no suicide attempt (HR-MOOD, N = 26); and 3. HR-MOOD with previous suicide attempt (HR-MOOD + SA, N = 20). Findings were tested in an independent cohort not selected for family history (HV, MOOD, and MOOD + SA, total N = 185). We tested for regional BPND differences and whether brain-wide patterns distinguished between groups. Low ventral prefrontal 5-HT1A BPND was associated with lifetime mood disorder diagnosis and suicide attempt, but only in subjects with a family history of mood disorder and suicide attempt. Brain-wide 5-HT1A BPND patterns including low ventral prefrontal and mesiotemporal cortical binding distinguished HR-MOOD + SA from HV. A biological endophenotype associated with resilience was not observed. Low ventral prefrontal 5-HT1A BPND may reflect familial mood disorder and suicide-related pathology. Further studies are needed to determine if higher ventral prefrontal 5-HT1A BPND confers resilience, reducing risk of suicidal behavior in the context of familial risk, and thereby offer a potential prevention target.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Data availability
The derived, de-identified data that support the findings of this study are available upon reasonable request from the corresponding authors. The raw data are not publicly available as participants of this study did not agree for their data to be shared publicly.
References
Blier P, de Montigny C, Chaput Y. A role for the serotonin system in the mechanism of action of antidepressant treatments: preclinical evidence. J Clin Psychiatry. 1990;51:14–20.
Kendler KS, Aggen SH, Neale MC. Evidence for multiple genetic factors underlying DSM-IV criteria for major depression. JAMA Psychiatry Chic Ill. 2013;70:599–607.
Mann JJ, Brent DA, Arango V. The neurobiology and genetics of suicide and attempted suicide: a focus on the serotonergic system. Neuropsychopharmacology. 2001;24:467–77.
Schmaal L, van Harmelen AL, Chatzi V, Lippard ETC, Toenders YJ, Averill LA, et al. Imaging suicidal thoughts and behaviors: a comprehensive review of 2 decades of neuroimaging studies. Mol Psychiatry. 2020;25:408–27.
Wang L, Zhou C, Zhu D, Wang X, Fang L, Zhong J, et al. Serotonin-1A receptor alterations in depression: a meta-analysis of molecular imaging studies. BMC Psychiatry. 2016;16:319.
Mann JJ, Bortinger J, Oquendo MA, Currier D, Li S, Brent DA. Family history of suicidal behavior and mood disorders in probands with mood disorders. Am J Psychiatry. 2005;162:1672–9.
Weissman MM, Berry OO, Warner V, Gameroff MJ, Skipper J, Talati A, et al. A 30-year study of 3 generations at high risk and low risk for depression. JAMA Psychiatry. 2016;73:970–7.
Innis RB, Cunningham VJ, Delforge J, Fujita M, Gjedde A, Gunn RN, et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab. 2007;27:1533–9.
Parsey RV, Ogden RT, Miller JM, Tin A, Hesselgrave N, Goldstein E, et al. Higher serotonin 1A binding in a second major depression cohort: modeling and reference region considerations. Biol Psychiatry. 2010;68:170–8.
Parsey RV, Oquendo MA, Ogden RT, Olvet DM, Simpson N, Huang YY. et al. Altered serotonin 1A binding in major depression: a [carbonyl-C-11]WAY100635 positron emission tomography study. Biol Psychiatry. 2006;59:106–13.
Miller JM, Brennan KG, Ogden TR, Oquendo MA, Sullivan GM, Mann JJ, et al. Elevated serotonin 1A binding in remitted major depressive disorder: evidence for a trait biological abnormality. Neuropsychopharmacol Publ Am Coll Neuropsychopharmacol. 2009;34:2275–84.
Milak MS, Pantazatos S, Rashid R, Zanderigo F, DeLorenzo C, Hesselgrave N, et al. Higher 5-HT 1A autoreceptor binding as an endophenotype for major depressive disorder identified in high risk offspring – A pilot study. Psychiatry Res Neuroimaging. 2018;276:15–23.
Hendry N, Christie I, Rabiner EA, Laruelle M, Watson J. In vitro assessment of the agonist properties of the novel 5-HT1A receptor ligand, CUMI-101 (MMP), in rat brain tissue. Nucl Med Biol. 2011;38:273–7.
Kumar JSD, Milak MS, Majo VJ, Prabhakaran J, Mali P, Savenkova L, et al. Comparison of high and low affinity serotonin 1A receptors by PET in vivo in nonhuman primates. J Pharm Sci. 2012;120:254–7.
Drevets WC, Thase M, Moses E, Price J, Frank E, Kupfer DJ, et al. Serotonin-1A receptor imaging in recurrent depression: replication and literature review. Nucl Med Biol. 2007;34:865–77. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2702715/
Sullivan GM, Ogden RT, Oquendo MA, Kumar JSD, Simpson N, Huang YYU, et al. Positron emission tomography quantification of serotonin-1A receptor binding in medication-free bipolar depression. Biol Psychiatry. 2009;66:223–30.
Brent DA, Melhem NM, Oquendo M, Burke A, Birmaher B, Stanley B, et al. Familial pathways to early-onset suicide attempt: a 5.6-year prospective study. JAMA Psychiatry. 2015;72:160–8.
Melhem NM, Porta G, Oquendo MA, Zelazny J, Keilp JG, Iyengar S, et al. Severity and variability of depression symptoms predicting suicide attempt in high-risk individuals. JAMA Psychiatry. 2019;76:603–13.
Zanderigo F, Ogden RT, Parsey RV. Reference region approaches in PET: a comparative study on multiple radioligands. J Cereb Blood Flow Metab J Int Soc Cereb Blood Flow Metab. 2013;33:888–97.
Avants BB, Tustison NJ, Stauffer M, Song G, Wu B, Gee JC. The Insight ToolKit image registration framework. Front Neuroinformatics. 2014 Apr [cited 2021 Feb 23];8. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4009425/
Eklund A, Nichols TE, Knutsson H. Cluster failure: Why fMRI inferences for spatial extent have inflated false-positive rates. Proc Natl Acad Sci USA. 2016;113:7900–5.
Slotnick SD. Cluster success: fMRI inferences for spatial extent have acceptable false-positive rates. Cogn Neurosci. 2017;8:150–5.
Cox RW, Chen G, Glen DR, Reynolds RC, Taylor PA. FMRI clustering in AFNI: false-positive rates redux. Brain Connect. 2017;7:152–71.
Vapnik VN. An overview of statistical learning theory. IEEE Trans Neural Netw Publ IEEE Neural Netw Counc. 1999;10:988–99.
Drevets WC, Frank E, Price JC, Kupfer DJ, Holt D, Greer PJ, et al. PET imaging of serotonin 1A receptor binding in depression. Biol Psychiatry. 1999;46:1375–87.
Sargent PA, Kjaer KH, Bench CJ, Rabiner EA, Messa C, Meyer J, et al. Brain serotonin1A receptor binding measured by positron emission tomography with [11C]WAY-100635: effects of depression and antidepressant treatment. Arch Gen Psychiatry. 2000;57:174–80.
Shively CA, Friedman DP, Gage HD, Bounds MC, Brown-Proctor C, Blair JB, et al. Behavioral depression and positron emission tomography-determined serotonin 1A receptor binding potential in cynomolgus monkeys. Arch Gen Psychiatry. 2006;63:396–403.
Bhagwagar Z, Rabiner EA, Sargent PA, Grasby PM, Cowen PJ. Persistent reduction in brain serotonin1A receptor binding in recovered depressed men measured by positron emission tomography with [11C]WAY-100635. Mol Psychiatry. 2004;9:386–92.
Melhem N, Zhong Y, Miller J, Zanderigo F, Ogden RT, Sublette ME, et al. Brain 5-HT1A Receptor PET binding, cortisol responses to stress, and the familial transmission of suicidal behavior [Internet]. PsyArXiv; 2021 [cited 2021 Feb 26]. Available from: https://psyarxiv.com/at7zj/
Davey CG, Breakspear M, Pujol J, Harrison BJ. A brain model of disturbed self-appraisal in depression. Am J Psychiatry. 2017;174:895–903.
Arango V, Underwood MD, Gubbi AV, Mann JJ. Localized alterations in pre- and postsynaptic serotonin binding sites in the ventrolateral prefrontal cortex of suicide victims. Brain Res. 1995;688:121–33.
Drevets WC. Orbitofrontal cortex function and structure in depression. Ann N. Y Acad Sci. 2007;1121:499–527.
Wiggins JL, Brotman MA, Adleman NE, Kim P, Wambach CG, Reynolds RC, et al. Neural Markers in Pediatric Bipolar Disorder and Familial Risk for Bipolar Disorder. J Am Acad Child Adolesc Psychiatry. 2017;56:67–78.
Shrestha S, Hirvonen J, Hines CS, Henter ID, Svenningsson P, Pike VW, et al. Serotonin-1A receptors in major depression quantified using PET: controversies, confounds, and recommendations. NeuroImage. 2012;59:3243–51.
Gray NA, Milak MS, DeLorenzo C, Ogden RT, Huang YY, Mann JJ, et al. Antidepressant treatment reduces serotonin-1A autoreceptor binding in major depressive disorder. Biol Psychiatry. 2013;74:26–31.
Funding
This study was supported by National Institute of Mental Health MH108039 (NMM) MH056390, 5P50MH090964 and 5R01MH040695 (JJM) and American Foundation for Suicide Prevention (AFSP) SRG-0-102-16 (SPP). The funding sources did not participate in the design and conduct of the study; in the collection, management, analysis, and interpretation of the data; or in the preparation, review, or approval of the manuscript.
Author information
Authors and Affiliations
Contributions
The authors confirm contribution to the paper as follows. Study conception and design: NMM, DAB, JJM; data collection: NMM, DAB, AB, JMM, JJM; analysis, analysis conception, and interpretation of results: SPP, FZ, EAB, ML, JJM; original draft manuscript preparation: SPP; manuscript review and editing: SPP, NMM, DAB, FZ, EAB, ML, JMM, JJM. All authors reviewed the results and approved the final version of the manuscript.
Corresponding authors
Ethics declarations
Competing interests
Authors SPP, NMM, FZ, ML, EAB, JMM have no conflicts of interest to report. JJM and AB receive royalties for commercial use of the C-SSRS from the Research Foundation for Mental Hygiene. DAB receives research support from NIMH, AFSP, the Once Upon a Time Foundation, and the Beckwith Foundation, receives royalties from Guilford Press, from the electronic self-rated version of the C-SSRS from eRT, Inc., and from performing duties as an UptoDate Psychiatry Section Editor, receives consulting fees from Healthwise, receives Honoraria from the Klingenstein Third Generation Foundation for scientific board membership and grant reviews, and is a scientific board member for AFSP. Intellectual Property, currently with no financial interest: Funding from the National Institute of Mental Health supported the development of intellectual property for BRITE, the As Safe As Possible intervention, the Computerized Adaptive Screen for Suicidal Youth (CASSY) measure, a suicide risk machine learning algorithm, and the Screening Wizard screening tool.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Rights and permissions
About this article
Cite this article
Pantazatos, S.P., Melhem, N.M., Brent, D.A. et al. Ventral prefrontal serotonin 1A receptor binding: a neural marker of vulnerability for mood disorder and suicidal behavior?. Mol Psychiatry 27, 4136–4143 (2022). https://doi.org/10.1038/s41380-022-01671-y
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41380-022-01671-y